PAS adds money man as acting President 2019-04-01 10:33 ET - News Release
Dr. Patrick Gray reports
PASCAL BIOSCIENCES NAMES CARL WEISSMAN ACTING PRESIDENT
Carl Weissman has joined Pascal Biosciences Inc. in the role of acting president. Mr. Weissman is a veteran of the biotechnology industry, with more than two decades of experience that spans investing, founding and managing emerging biotech companies. Dr. Patrick Gray will continue in his role as chief executive officer and a director of the company.
Mr. Weissman most recently served as a biotech investment advisor for Lightspeed Venture Partners, a venture capital firm focused on accelerating innovations and trends in enterprise and consumer sectors. Prior to that, he served as consulting chief executive officer of OSS Healthcare, a joint venture of MPM Capital and Novartis Oncology. In 2003, he co-founded Accelerator Corp. (now known as Accelerator Life Science Partners), a joint investment vehicle backed by a syndicate of venture capital firms. From 2003 to 2014, he served as chief executive officer and chairman at Accelerator as well as all 10 companies invested in and managed by Accelerator. Mr. Weissman was also previously a venture partner at MPM Capital. While at MPM, he served as president and chief executive officer of Centagenetix, a human genetics company in Cambridge, Mass. Prior to joining MPM, he spent six years at Prolinx Inc., where he held a number of positions, culminating as the head of both finance and business development.
"Carl's vast experience in directing and funding innovative companies in the biotechnology sector is invaluable and will serve Pascal well as we continue to advance our leading therapeutic product candidates and build shareholder value," said Dr. Patrick Gray, chief executive officer of Pascal.
"Pascal Biosciences has an exciting and promising product pipeline that includes groundbreaking molecules specifically for brain cancers and, more broadly, enhancing checkpoint inhibitors," said Mr. Weissman. "It's rewarding to be involved in helping to further advance these opportunities to a point where they may substantially improve patient outcomes."